Skip to main content

Advertisement

Log in

Increasing Syringe Access and HIV Prevention in California: Findings from a Survey of Local Health Jurisdiction Key Personnel

  • Published:
Journal of Urban Health Aims and scope Submit manuscript

Abstract

This article presents results from the first survey of California local health jurisdictions (LHJs) subsequent to passage of legislation that allows for over-the-counter pharmacy sales of syringes. In 2004 Governor Arnold Schwarzenegger signed Senate Bill 1159 (SB1159) into law to “prevent the spread of HIV, hepatitis and other blood-borne disease among drug users, their sexual partners and their children.” This legislation permits counties and cities to authorize a local disease prevention demonstration project (DPDP). Once authorized, a DPDP permits individuals to legally purchase and possess up to ten syringes from registered pharmacies without a doctor’s prescription. From June to August 2005, we surveyed health departments in all 61 LHJs to assess implementation status of SB1159. Fifty-seven (93%) LHJs responded. Nine (16%) had approved a DPDP by August 2005, 17 (30%) were in the process of obtaining authorization, and 18 (32%) anticipated that SB1159 would never be authorized in their LHJ. Among LHJs that do not plan to approve a DPDP (n = 18), the reasons included: strong community opposition (41%), competing priorities (35%), law enforcement opposition (29%), and little or no interest among pharmacies (29%). In LHJs that have authorized a DPDP, 31.4% of pharmacies registered to legally sell nonprescription syringes. Preliminary results indicate that local coalitions, comprised of public health, waste management and pharmacy officials, have been instrumental in facilitating DPDP authorization. Further research is needed to identify facilitators and barriers to adopting SB1159, to identify areas for improving technical assistance to implementers, and to assess the public health impact of the legislation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1

Similar content being viewed by others

References

  1. California Department of Health Services Office of AIDS. Cumulative AIDS case data through January 31, 2006. Accessed on March 7, 2006. Available at: http://www.dhs.ca.gov/aids/Statistics/pdf/Stats2006/Jan06AIDSmerged.pdf.

  2. Facer MS, Ritieni A, Marino J, et al. Consensus Meeting on HIV/AIDS Incidence and Prevalence in California. Sacramento: California Department of Health Services; 2001.

    Google Scholar 

  3. California Department of Health Services. The Hepatitis C Strategic Plan. A Collaborative Approach to the Emerging Epidemic in California. Sacramento: Disease Investigations and Surveillance Branch, Hepatitis C Prevention and Control Unit; 2001.

    Google Scholar 

  4. Williams IT. Epidemiology of hepatitis C in the United States. Am J Med. 1999;107:2S–9S.

    Article  PubMed  CAS  Google Scholar 

  5. Burris S, Vernick J, Ditzler A, Strathdee S. The legality of selling or giving syringes to injection drug users. J Am Pharm Assoc. 2002;42(Suppl 2):S13–S18.

    Google Scholar 

  6. Singer M, Baer H, Scott G, Horowitz S, Weinstein B. Pharmacy access to syringes among injection drug users: follow-up findings from Hartford, Connecticut. Public Health Rep. 1998;113(Suppl 1):81–89.

    PubMed  Google Scholar 

  7. Compton WM, Horton JC, Cottler LB, et al. A multistate trial of pharmacy syringe purchase. J Urban Health. 2004;81:661–670.

    PubMed  Google Scholar 

  8. Stopka TJ, Singer M, Teng W, et al. Pharmacy access to over-the-counter syringes in Connecticut: implications for HIV and hepatitis prevention among injection drug users. AIDS Public Policy J. 2002;17:115–126.

    Google Scholar 

  9. Fuller CM, Ahern J, Vadnai L, et al. Impact of increased syringe access: preliminary findings on injection drug user syringe source, disposal, and pharmacy sales in Harlem, New York. J Am Pharm Assoc. 2002;42(Suppl 2):S77–S82.

    Google Scholar 

  10. Pouget ER, Deren S, Fuller CM, et al. Receptive syringe sharing among injection drug users in Harlem and the Bronx during the New York State expanded syringe access demonstration program. J Acquir Immune Defic Syndr. 2005;39:471–477.

    Article  PubMed  Google Scholar 

  11. Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41:777–813.

    Article  PubMed  Google Scholar 

  12. Friedman SR, Perlis T, Des Jarlais DC. Laws prohibiting over-the-counter syringe sales to injection drug users: relations to population density, HIV prevalence, and HIV incidence. Am J Public Health. 2001;91:791–793.

    Article  PubMed  CAS  Google Scholar 

  13. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large U.S. metropolitan areas. Am J Public Health. 1996;86:642–654.

    PubMed  CAS  Google Scholar 

  14. Jones TS, Coffin PO. Preventing blood-borne infections through pharmacy syringe sales and safe community syringe disposal. J Am Pharm Assoc. 2002;42(Suppl 2):S6–S9.

    Google Scholar 

  15. Reich W, Compton WM, Horton JC, et al. Injection drug users report good access to pharmacy sale of syringes. J Am Pharm Assoc. 2002;42(Suppl 2):S68–S72.

    Google Scholar 

  16. Junge B, Vlahov D, Riley E, Huettner S, Brown M, Beilenson P. Pharmacy access to sterile syringe for injection drug users: attitudes of participants in a syringe exchange program. J Am Pharm Assoc (Wash.). 1999;39:17–22.

    CAS  Google Scholar 

  17. Valleroy LA, Weinstein B, Jones TS, Groseclose SL, Rolfs RT, Kassler WJ. Impact of increased legal access to needles and syringes on community pharmacies’ needle and syringe sales—Connecticut, 1992–1993. J Acquir Immune Defic Syndr. 1995;10:73–81.

    CAS  Google Scholar 

  18. Wright-De Aguero L, Weinstein B, Jones TS, Miles J. Impact of change in Connecticut syringe prescription laws on pharmacy sales and pharmacy managers’ practices. J Acquir Immune Defic Syndr. 1998;18(Suppl 1):102–110.

    Google Scholar 

  19. Groseclose SL, Weinstein B, Jones T, et al. Impact of increased legal access to needles and syringes on practices of injecting-drug users and police officers—Connecticut, 1992–1993. J Acquir Immune Defic Syndr. 1995;10:82–89.

    CAS  Google Scholar 

  20. Singer M, Himmelgreen D, Weeks MR, Radda KE, Martinez R. Changing the environment of AIDS risk: findings on syringe and pharmacy sales of syringes in Hartford, Connecticut. Med Anthropol. 1997;18:107–130.

    Article  PubMed  CAS  Google Scholar 

  21. Riley ED, Safaeian M, Strathdee SA, et al. Comparing new participants of a mobile versus a pharmacy-based needle exchange program. J Acquir Immune Defic Syndr. 2000;24:57–61.

    PubMed  CAS  Google Scholar 

  22. Farley TA, Niccolai LM, Billeter M, Kissinger PJ, Grace M. Attitudes and practices of pharmacy managers regarding needle sales to injection drug users. J Am Pharm Assoc. 1999;39:23–26.

    CAS  Google Scholar 

  23. Gleghorn AA, Gee G, Vlahov D. Pharmacists’ attitudes about pharmacy sale of needles/syringes and needle exchange programs in a city without needle/syringe prescription laws. J Acquir Immune Defic Syndr. 1998;18(Suppl 1):89–93.

    Google Scholar 

  24. Reich W, Compton WM, Horton JC, et al. Pharmacist ambivalence about over-the-counter sale of syringes to injection drug users. J Am Pharm Assoc. 2002;42(Suppl 2):S52–S57.

    Google Scholar 

  25. Singer M, Stopka T. Diminishing access to over-the-counter (OTC) syringes among injection drug users in Hartford, CT: A longitudinal assessment. Paper presented at 3rd Annual CIRA Science Day. September 21, 2000. Yale University, Dept. of Epidemiology and Public Health. New Haven, Connecticut.

  26. Legislative Counsel. State of California. Official California Legislative Information. Accessed on August 16, 2006. Available at: http://www.leginfo.ca.gov.

  27. SPSS Inc. SPSS Base 13.0 for Windows User’s Guide. Chicago, Illinois: SPSS Inc.; 2004.

Download references

Acknowledgments

The authors wish to acknowledge the California SB1159 Evaluation Advisory Panel which provided helpful guidance and feedback on the LHJ Survey Instrument and overall evaluation activities. We also wish to thank John Keasling for creation of the California Pharmacy Sales of Syringes Map and Shante Brown for assistance with data entry. Finally, we wish to acknowledge the assistance of the California Conference on Local Health Officers, The California Conference of Local AIDS Directors, the California Health Executives Association of California, and all LHJ staff who took the time to complete the SB1159 survey.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Thomas J. Stopka MHS.

Additional information

Stopka, Ross, and Truax are with the Office of AIDS, California Department of Health Services, Sacramento, CA, USA; Garfein is with the School of Medicine, University of California, San Diego, San Diego, CA, USA.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stopka, T.J., Garfein, R.S., Ross, A. et al. Increasing Syringe Access and HIV Prevention in California: Findings from a Survey of Local Health Jurisdiction Key Personnel. J Urban Health 84, 116–125 (2007). https://doi.org/10.1007/s11524-006-9122-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11524-006-9122-x

Keywords

Navigation